엘루티아(ELUT)는 NASDAQ에 상장된 Healthcare · Medical Devices 기업입니다. 현재가 $0.94 (+9.38%), 시가총액 $0.05B, 52주 범위 $0.51 ~ $2.46.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconst
엘루티아의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
엘루티아의 현재 주가는 $0.94 (+9.38%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
엘루티아의 시가총액은 약 $0.05B입니다.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women'